Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 11

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 11
---
 stockholders’ equity$4,783 $17,295 

The accompanying notes are an integral part of these financial statements.

F-3

INTENSITY THERAPEUTICS, INC.

STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

Years Ended December 31,20242023Operating expenses:Research and development$10,496 $4,786 General and administrative6,089 3,533 Total operating expenses16,585 8,319 Loss from operations(16,585)(8,319)Other income (expense):Interest income314 324 Interest expense- (305)Loss on debt extinguishment- (2,262)Other income, net3 24 Net loss$(16,268)$(10,538)Preferred stock deemed dividend- (1,324)Net loss attributable to common stockholders$(16,268)$(11,862)Loss per share, basic and diluted$(1.17)$(1.38)Weighted average number of shares of common stock, basic and diluted13,906,9738,616,324

The accompanying notes are an integral part of these financial statements.

F-4

INTENSITY THERAPEUTICS, INC.

STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY)

(in thousands, except share amounts)

Series A Redeemable Convertible Preferred StockSeries B Convertible PreferredSeries C Convertible PreferredCommon StockAdditional Paid in CapitalAccumulated DeficitStockholders’ Equity (Deficiency)SharesAmountSharesAmountSharesAmountSharesAmountBalances at December 31, 20225,000,000$10,000 1,449,113$- 1,800,606$- 3,410,103$- $23,555 $(38,653)$(15,098)Issuance of common stock in public offering for cash, net of $3,403 issuance costs-- -- -- 4,485,0001 19,022 - 19,023  Issuance of warrants underwriters in connection with public offering -- -- -- -- 1,170 - 1,170  Conversion of preferred stock into common stock (5,000,000)(10,000)(1,449,113)- (1,800,606)- 4,124